viewAdvanced Oncotherapy PLC

Advanced Oncotherapy rises as it obtains international quality standard for LIGHT system

ISO 13485:2016 is an international quality standard that ensures the consistent design, development, production, installation and sale of medical devices

Protons about to collide
The LIGHT system uses a proton beam to treat tumours in patients

Advanced Oncotherapy PLC (LON:AVO) shares rose in mid-morning trading Monday after it received a quality standard certification for its LIGHT proton therapy system following an audit by compliance firm Lloyd’s Register.

ISO 13485:2016 is an internationally recognised quality standard that ensures the consistent design, development, production, installation and sale of medical devices that are safe for their intended purposes.

READ: Advanced Oncotherapy raises £10mln at a premium

The company said the certification was an important milestone that would allow it to continue developing its LIGHT system in compliance with the highest safety and product performance standards.

It would also allow it to make the product available for patient treatment once the medical device file had been approved.

The LIGHT system is focused on the use of protons, small sub-atomic particles, to treat tumour growths in patients using an accelerator beam similar to that of linear x-rays currently used in cancer treatment.

AVO is currently focused on increasing the power of the LIGHT proton beam to 230 mega-electron volts, the level required to treat deep-seated tumours in patients.

Dr Michel Baelen, the company’s director of regulatory affairs, said the compliance with the quality standard illustrated the importance the firm placed on the quality of its product, as well as “dedication to ensuring that the infrastructure to develop and manufacture our product is safe, effective and reliable”.

AVO shares were up 1.3% at 39p.

--Adds share price--

Quick facts: Advanced Oncotherapy PLC

Price: 39 GBX

Market: LSE
Market Cap: £95.33 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Advanced Oncotherapy PLC named herein, including the promotion by the Company of Advanced Oncotherapy PLC in any Content on the Site, the...



Morning Report: Advanced Oncotherapy sells proton beam cancer system for €50mln

Headlines from the Proactive UK newsroom. Advanced Oncotherapy (LON:AVO) has sold a proton beam cancer treatment system to a hospital in Cyprus for €50mln. Installation of the three-room system will begin before the end of 2023. ReNeuron (LON:RENE) has published clinical data from the...

1 day, 11 hours ago

2 min read